Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ACET

Adicet Bio Inc

Dec 13 • 04:00PM ET

0.9648

Dollar change -0.0096
Percentage change -0.99	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP FATE NTLA ALLO AGIO GILD BLUE EDIT IMTX SGMO

| Held by: VTI VXF FESM IWC CNCR CHNA BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.71	Insider Own	19.64%	Shs Outstand	82.40M	Perf Week	-8.11%
Market Cap	78.72M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	0.00%	Shs Float	66.22M	Perf Month	-15.37%
Income	-117.88M	PEG	-	EPS next Q	-0.35	Inst Own	51.43%	Short Float	4.52%	Perf Quarter	-35.68%
Sales	0.00M	P/S	-	EPS this Y	53.78%	Inst Trans	-17.68%	Short Ratio	5.29	Perf Half Y	-28.53%
Book/sh	2.57	P/B	0.38	EPS next Y	-0.82%	ROA	-49.20%	Short Interest	2.99M	Perf Year	-36.53%
Cash/sh	2.48	P/C	0.39	EPS next 5Y	-	ROE	-58.04%	52W Range	0.89 - 3.77	Perf YTD	-48.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.75%	ROI	-52.06%	52W High	-74.41%	Beta	1.87
Dividend TTM	-	Quick Ratio	10.64	Sales past 5Y	342.10%	Gross Margin	-	52W Low	8.89%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	10.64	EPS Y/Y TTM	49.12%	Oper. Margin	-	RSI (14)	38.08	Volatility	7.09% 9.19%
Employees	143	Debt/Eq	0.09	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.50	Target Price	6.40
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	71.09%	Payout	-	Rel Volume	1.24	Prev Close	0.97
Sales Surprise	-	EPS Surprise	0.15%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	565.15K	Price	0.96
SMA20	-4.39%	SMA50	-20.93%	SMA200	-36.79%	Trades		Volume	699,379	Change	-0.99%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Resumed	Guggenheim	Buy	$7
Sep-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-23	Downgrade	Guggenheim	Buy → Neutral
Jun-01-23	Downgrade	JP Morgan	Overweight → Neutral	$20 → $6
Sep-21-22	Initiated	JP Morgan	Overweight	$23
Mar-31-22	Initiated	SMBC Nikko	Outperform	$28
Mar-08-22	Initiated	Truist	Buy	$30
Mar-04-22	Initiated	Jefferies	Buy	$27
May-18-21	Initiated	BTIG Research	Buy	$34
Apr-23-21	Initiated	H.C. Wainwright	Buy	$27
Apr-14-21	Initiated	Canaccord Genuity	Buy	$28
Apr-08-21	Initiated	Guggenheim	Buy	$22
Nov-04-20	Initiated	B. Riley Securities	Buy	$30
Oct-27-20	Initiated	JMP Securities	Mkt Outperform	$30
Oct-16-20	Initiated	Wedbush	Outperform	$25

Show Previous Ratings

Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
07:00AM	Loading…
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:00PM	Loading…
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
05:41PM	Loading…
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)
Apr-01-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-24 05:19PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:35AM	Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +7.35%
Mar-19-24 09:53PM	ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 (InvestorPlace) +5.42%
04:10PM	Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Mar-15-24 09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Mar-11-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 07:46PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 09:40AM	Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-12-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-05-24 04:01PM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-31-24 04:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-30-24 12:51PM	Hedge Fund and Insider Trading News: Larry Robbins, Ray Dalio, Two Sigma Investments, Point72 Asset Management, Bluebell Capital Partners, Adicet Bio Inc (ACET), Netflix, Inc. (NFLX), and More (Insider Monkey)
Jan-25-24 04:01PM	Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire)
09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-22-24 11:43PM	Adicet Bio, Inc. Announces Pricing of Public Offering (Business Wire)
04:28PM	Adicet Bio, Inc. Announces Proposed Public Offering (Business Wire)
Jan-04-24 07:00AM	Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 (Business Wire) +22.73%
Jan-03-24 04:01PM	Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook (Business Wire) -12.44%
Dec-29-23 04:50PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.62% +6.35%
Dec-10-23 12:00PM	Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-08-23 04:10PM	Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire) -6.02%
Nov-07-23 07:00AM	Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference (Business Wire) -8.04%
Nov-02-23 09:00AM	Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire) +13.85%
Oct-31-23 06:25PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-04-23 12:00PM	Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference (Business Wire)
Sep-29-23 05:24PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-23 09:00AM	Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (Business Wire)
Aug-31-23 04:35PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.11%
Aug-12-23 08:16AM	Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely? (Simply Wall St.)
Aug-09-23 04:15PM	Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire) +11.90%
Aug-02-23 04:00PM	Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-31-23 04:50PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.24%
Jul-11-23 08:30AM	Adicet Announces Appointment of Katie Peng to the Board of Directors (Business Wire)
Jun-30-23 04:51PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19% +12.35%
Jun-26-23 04:00PM	Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NHL) (Business Wire) -54.29%
Jun-01-23 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference (Business Wire) -5.20%
May-31-23 04:53PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 06:00AM	Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting (Business Wire)
May-09-23 04:30PM	Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference (Business Wire)
04:10PM	Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Apr-28-23 05:13PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-17-23 06:58AM	Adicet Bio, Inc.'s (NASDAQ:ACET) Price Is Out Of Tune With Revenues (Simply Wall St.) +9.45%
Apr-13-23 07:00AM	Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire) +9.68%
Apr-04-23 02:47PM	Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound (TipRanks) -6.14%
Mar-31-23 04:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 04:01PM	Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 07:00AM	Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit (Business Wire)
Mar-05-23 07:09AM	Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-28-23 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-23 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference (Business Wire)
Jan-31-23 08:40PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.29%
Dec-30-22 04:43PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-20-22 08:23AM	Shareholders in Adicet Bio (NASDAQ:ACET) have lost 49%, as stock drops 22% this past week (Simply Wall St.)
Dec-10-22 10:00AM	Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NHL) (Business Wire)
Dec-02-22 07:00AM	Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NHL) (Business Wire)
Nov-30-22 08:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:00PM	Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit (Business Wire)

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kauffman Michael	Director	Jun 05 '24	Sale	1.43	5,900	8,437	5,900	Jun 07 04:05 PM
ORBIMED ADVISORS LLC	Director	Jan 25 '24	Buy	2.40	3,125,000	7,500,000	7,526,359	Jan 26 07:14 PM
GORDON CARL L	Director	Jan 25 '24	Buy	2.40	3,125,000	7,500,000	7,526,359	Jan 26 07:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACET

Adicet Bio Inc

Upgrade your FINVIZ experience